Drugs /

talquetamab

Back to Drugs List

Overview

NCI Definition [1]:
A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, anti-CD3/anti-GPRC5D bispecific monoclonal antibody JNJ-64407564 binds to both CD3 on T-cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells. GPRC5D is overexpressed on certain tumors, such as multiple myeloma, while minimally expressed on normal, healthy cells, and plays a key role in tumor cell proliferation.

Clinical Trials

View Clinical Trials for talquetamab

Talquetamab has been investigated in 3 clinical trials, of which 3 are open and 0 are closed. Of the trials investigating talquetamab, 2 are phase 1 (2 open) and 1 is phase 2 (1 open).

Multiple myeloma is the most common disease being investigated in talquetamab clinical trials [2].

Drug Details

Synonyms [2]:
jnj64407564, jnj-64407564, jnj 64407564, humanized gprc5d x cd3 duobody antibody jnj-64407564, gprc5d/cd3 duobody antibody jnj-64407564, gprc5d x cd3 duobody antibody jnj-64407564, gprc5d x cd3 bispecific antibody jnj-64407564, anti-cd3/anti-gprc5d bispecific monoclonal antibody jnj-64407564
Drug Target(s) [2]:
CD3, GPRC5D
NCIT ID [1]:
C147534

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.